PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition...
Arthur Klausner to speak at FundingPost's early-stage VC breakfast in New York City on May 18
News | 05. 18. 2006
